Array-based platform for multiplexed protein and nucleic acid assays
VTT's Array-in-Well platform contains a microarray in each well of a 96-well microtitre plate. The microarray, printed at the bottom of the well, can consist of e.g. capture antibodies, antigens, peptides or oligonucleotides.
The array-based system enables simultaneous measurement of several analytes in parallel, bringing savings in both working time and reagent costs.
Users of the multiplexed platform benefit from the parallelisation of assays, being able to gather more information from their biological samples.
New applications are constantly being developed on this versatile platform – please enquire about the possibility of setting up a multiplexed assay for your needs.
An 8-plex assay detecting respiratory viruses was developed for a clinical virology laboratory
We have developed an 8-plex virus antigen assay for a virology unit affiliated with Turku University Central Hospital. According to Docent Matti Waris, the assay had excellent concordance with the existing single in-house tests, and the new multiplexed assay was used in a research study consisting of more than 6,000 samples from small children and their families.
Assay know-how and biomolecule modification techniques are the key to success
We have a deep understanding of the bioassay dynamics in the array-in-well context which we utilise in the assay development for new applications. The other core competences are the modification of biomolecules, labelling, immobilisation, and the design of novel nucleic acid probes.
Multiplexed assays have been developed for several protein biomarkers for e.g. prostate cancer and cardiac disease diagnostics, as well as nucleic acid markers for human genotyping (21 HLA alleles) and pathogen identification and subtyping (Enteroviruses, Influenza).
The current research focus areas are autoimmune disease, serological profiling of autoantibody responses using antigen arrays, and a novel nucleic acid probe technology for pathogen typing (patent pending).